ISPOR Budget Impact Analysis Good Practices

What it is

— The ISPOR Budget Impact Analysis (BIA) Good Practices reports are consensus methods guidance issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) through its Good Practices for Outcomes Research task forces. The current canonical statement is the 2012 Budget Impact Analysis Good Practice II report (Sullivan et al., Value in Health, 2014), which updates the original 2007 task force report (Mauskopf et al.). It defines what a budget impact analysis is, the analytic framework it should follow, the inputs it requires, and how it must be reported. A BIA estimates the financial consequences of adopting and diffusing a new intervention within a specific population and a specific budget holder's accounts — typically a health plan, national payer, hospital, or integrated delivery system. It answers "can we afford this, and what will it do to our budget over the next few years?", which is a fundamentally different question from the value-for-money question answered by cost-effectiveness analysis (CEA). Most HTA submissions and payer dossiers require a BIA alongside (and distinct from) the economic evaluation.

When to use

— Use a BIA whenever a decision maker who holds a budget needs to understand the near-term, total financial impact of a coverage, formulary, or adoption decision: payer P&T / formulary reviews, HTA affordability assessments (e.g., NICE budget impact test, ICER's potential-budget-impact analysis), hospital pharmacy and value-analysis committees, and the budget-impact module of an AMCP-style or country-specific reimbursement dossier. The defining decision rules: (1) the perspective is the specific budget holder's (payer / health-system), not societal; (2) the time horizon is short (commonly 1–5 years) and reported year by year, undiscounted; (3) the comparator is the current treatment mix ("world without") versus the anticipated mix after adoption ("world with"), not a single head-to-head comparator. Choose a BIA when the question is affordability and cash-flow planning. Choose its sibling cost-effectiveness / cost-utility analysis when the question is whether the technology is worth its price per unit of health gained — the two are complementary and a complete dossier usually contains both, but they are not interchangeable.

What it requires

— The guideline enforces a specific structure and set of reportable elements: (1) a clearly stated perspective and budget holder, with the matching cost inventory; (2) an explicit eligible-population size built from epidemiology (prevalence/incidence), diagnosis and treatment rates, and any eligibility restrictions — sized for the open or closed population as appropriate; (3) the current and projected treatment mix, including realistic uptake / market-diffusion curves rather than instantaneous 100% switching; (4) per-patient cost streams disaggregated into intervention/drug acquisition costs, other medical costs, and cost offsets (e.g., avoided hospitalizations, displaced therapies); (5) a transparent model structure (a simple cost calculator, or a Markov/state-transition or discrete-event model when condition dynamics matter); (6) scenario and one-way sensitivity analyses on the dominant drivers (population size, uptake, market share, costs), with probabilistic sensitivity analysis optional rather than required; and (7) disaggregated annual results — total and per-member-per-month (PMPM) where relevant — so the budget holder can trace the cost components. Crucially, costs and outcomes are undiscounted and the horizon is short, which distinguishes BIA reporting from CEA.

When NOT to use — limitations and common misapplications

— A BIA is not a value assessment and must never be used to make a value-for-money claim ("our drug is cost-saving" / "cost-effective") — that is the job of CEA/cost-utility analysis, and conflating the two is the single most common misapplication. Specific failure modes: (a) applying a lifetime horizon or discounting — if you are discounting future costs you have likely drifted into building a CEA, not a BIA; (b) adopting a societal perspective and the wrong cost inventory instead of the budget holder's accounts; (c) assuming instantaneous full uptake instead of a realistic diffusion curve, which overstates early-year impact; (d) reporting only a single net cost figure without disaggregated drug, medical, and offset line items, defeating the payer's need to interrogate the components; (e) ignoring that eligible-population sizing and market-share uncertainty usually dominate the result far more than unit-cost precision, yet are often left unexplored in sensitivity analysis; and (f) treating the BIA as a marketing artifact rather than a budget-planning input. A BIA is also the wrong tool when the decision turns on health outcomes per dollar (use CEA) or when no defined budget holder exists.

How it maps to this catalog

— The BIA framework is implemented through several concepts in this catalog. Overall structure and model choice are covered by health-economic-modeling-methods-rwe, with dynamic structures in markov-transition-probabilities-rwe and discrete-event-simulation-rwe when condition progression must be modeled. The cost inputs are operationalized through healthcare-costs-pppm-pppy-pmpm (per-patient and per-member cost streams, including the PMPM reporting BIA favors), hcru-healthcare-resource-utilization (resource-use parameters), and all-cause-vs-attributable-costs-rwe (choosing the correct cost basis for offsets). The short-horizon, undiscounted convention is the key contrast captured in discounting-costs-effects-rwe — note that, unlike CEA, a BIA deliberately does not discount. Population transportability and uptake realism map to generalizability-transportability-external-validity-rwe, and uncertainty handling maps to probabilistic-sensitivity-analysis-hea-rwe (with the caveat that one-way/scenario analysis, not full PSA, is the BIA norm). The sibling-versus-distinct relationship is anchored to cost-effectiveness, and the decision-context concept is budget-impact. Applied note for claims/EHR/registry RWE: a BIA is a modeling exercise, but its most influential parameters — eligible-population size, current treatment patterns and market share, HCRU, and per-patient costs — are typically sourced from real-world claims, EHR, and registry data. The quality of a BIA therefore hinges on the fitness of those RWE inputs, even though the BIA framework itself prescribes no study design.